Siga Technologies, Inc.

New York, NY

UEI
VJRNRTSL22K4
CAGE
1V4X4
Primary NAICS
325412 Pharmaceutical Preparation Manufacturing
SAM.gov registration
Active through

Company facts

Self-certified in SAM.gov
  • For Profit Organization
  • Manufacturer of Goods
Entity structure
Corporate Entity (Not Tax Exempt)
SAM.gov registration date
Physical address
31 E 62nd St, New York, NY 10065, USA
Website
siga.com
Founded
1995
Employees
11-50
Estimated annual revenue
$100M-$250M
Industry
  1. Health Care
  2. Pharmaceuticals, Biotechnology & Life Sciences
  3. Pharmaceuticals
SIC code
28 Chemical & Allied Products
Profiles

Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .

Contract obligations by fiscal year

Fiscal year Obligated
FY2027 To date $0
FY2026 $2,068,321
FY2025 $53,123,168
FY2024 $122,643,795
FY2023 $143,679,930

Top agencies by obligations

Rank Agency Obligated, FY2026–FY2027 Share
1 Department of Health and Human Services $2,068,321

Contract awards

Award Agency Obligated Awarded
Procurement of 23,030 tpoxx oral courses and 50 tpoxx IV courses. To maintain national stockpile. W911SR24C0030 ACC Aberdeen Proving Ground $8,999,677
Procure up to 23000 tpoxx courses for small POX treatment. W911SR22C0051 ACC Aberdeen Proving Ground $11,752,417
Procure courses of FDA approved tpoxx drug/therapeutic W911SR22C0032 ACC Aberdeen Proving Ground $7,469,638
Procurement and late-stage development of smallpox antiviral drug(s) 75A50118C00019 Office of the Assistant Secretary for Preparedness and Response $626,506,870
Drugs and biologicals HHSO100201100001C Office of the Assistant Secretary for Preparedness and Response $518,482,778

Latest 5 listed here. See the rest on GovTribe.

Grant awards

Award Agency Obligated Awarded
Antiviral therapeutics for flavivirus infections R01AI093356 National Institute of Allergy and Infectious Diseases (NIH) $5,805,389
Broad-spectrum, small-molecule inhibitors of bunyaviruses U01AI082108 National Institutes of Health $1,667,535
Novel small molecule inhibitors of dengue replication R43AI079937 National Institutes of Health $963,737
Enhancing the immune response to antigens delivered by the bacterial vector, stre R43AI072905 National Institutes of Health $273,956
ST-246 treatment of smallpox vaccine-related adverse events in murine models R43AI075747 National Institutes of Health $293,399

Latest 5 listed here. See the rest on GovTribe.

Similar vendors

Vendor Location Primary NAICS
Emergent Product Development Gaithersburg Inc. UEI CNPVCR8DK7M8 Gaithersburg, MD 541714 Research and Development in Biotechnology (except Nanobiotechnology)
Emergent Biosolutions Canada Inc. UEI XM23STFMVML6 Winnipeg, MB 325412 Pharmaceutical Preparation Manufacturing
Endo Usa, Inc. UEI D739PJVW5JF9 Malvern, PA 325412 Pharmaceutical Preparation Manufacturing
Amgen Inc. UEI D92HARF1LKA9 Thousand Oaks, CA 325412 Pharmaceutical Preparation Manufacturing
Akanocure Pharmaceuticals Inc. UEI QMU8ZFLN2A34 West Lafayette, IN —

See more similar vendors on GovTribe

About the company

Written by GovTribe AI ·

Siga Technologies, Inc. is a for-profit corporate entity registered in SAM.gov since 2001, specializing in the manufacturing of pharmaceutical products with a focus on biodefense medical countermeasures. The company is primarily known for developing TPOXX (tecovirimat), an FDA-approved therapeutic medication used for treating smallpox and related viral infections. Based in New York, Siga Technologies has established itself as a key provider of specialized medical treatments for potential biological threat scenarios, with a significant portion of its business centered on supplying critical medical countermeasures to U.S. government agencies.

The company has consistently secured federal contract awards from the Department of Defense, specifically the Joint PEO Chemical and Biological Defense agency, for procuring courses of TPOXX. Recent contract awards demonstrate a pattern of supplying strategic medical stockpiles, including contracts for 23,030 oral and 50 intravenous TPOXX courses in August 2024, 23,000 TPOXX courses in September 2022, and 10,000 TPOXX courses in May 2022. These contracts, valued between $7.4 million and $11.7 million, are definitive firm fixed-price agreements with no specific small business set-aside designations. The contracts uniformly aim to replenish and maintain national medical stockpiles, focusing on therapeutic treatments for potential biological threats, particularly smallpox. Each contract has been awarded on a sole-source basis, highlighting Siga Technologies' unique position as the sole FDA-approved provider of this specific therapeutic treatment.

Quick answers

Is Siga Technologies, Inc. registered in SAM.gov?

Yes. Siga Technologies, Inc.'s SAM.gov registration is active through May 18, 2027.

How much has Siga Technologies, Inc. received in federal contracts?

Federal contracts obligated $53,123,168 to Siga Technologies, Inc. in fiscal year 2025 and $321,515,214 in fiscal years 2023 through 2027.

How does Siga Technologies, Inc. rank among federal contractors?

Siga Technologies, Inc. ranked #2 in PSC AN13, #9 in NAICS 541714 and #13 in PSC AN in FY2025.

What is Siga Technologies, Inc.'s most recent federal award?

Siga Technologies, Inc.'s most recent federal contract award is Procurement of 23,030 tpoxx oral courses and 50 tpoxx IV courses. To maintain national stockpile (W911SR24C0030), from ACC Aberdeen Proving Ground, on August 2, 2024.

On GovTribe

See Siga Technologies, Inc.'s full federal record

  • Federal contract awards
  • Federal grant awards
  • Funding analysis by agency, NAICS and set-aside
  • Similar vendors
Try for free Login